Two or three issues side by side. Only issues that are open, upcoming or awaiting listing appear — those are the ones a comparison can act on, and the ones whose figures are actually published.
Add another
| Comparing | SP Symbiotec PharmalabMainboard · Upcoming | HE Hy-Tech EngineersMainboard · Upcoming |
|---|---|---|
| Issue | ||
| Board | Mainboard | Mainboard |
| Status | Upcoming | Upcoming |
| Price band | ||
| ₹988 |
| ₹53 |
| Timeline | ||
|---|---|---|
| Open date | 24 Aug 2026 | 24 Aug 2026 |
| Close date | 27 Aug 2026 | 27 Aug 2026 |
| Allotment date | 28 Aug 2026 | 28 Aug 2026 |
| Listing date | 1 Sep 2026 | 1 Sep 2026 |
| Valuation | ||
|---|---|---|
| P/E ratioAt the upper band. Null where earnings are negative. | 51.73x | 19.63x |
| EPS | ₹19.1 | ₹2.7 |
| NAV per share | ₹184.69 | ₹14.61 |
| Return on equity | 11.19% | 20.24% |
| Return on net worth | 9.48% | 20.24% |
| Return on capital employed | 11.56% | 24.40% |
| EBITDA margin | 26.59% | 22.01% |
A row is shown only where at least one of these issues has published the figure; a dash means that company has not. Nothing here is a recommendation — CAPITA1 is not registered with SEBI as an investment adviser or a research analyst.